Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
Model No.: DM 1032900-25-6
Function: Specialist Drugs
Certification: FDA, SGS, GMP
Grade Standard: Medicine Grade
Type: Chemical Reagent
Volatile: Not Volatile
Appearence: White Powder
Packaging: As required
Top Quality API 99% Ceritinib 1032900-25-6
Product Name: Ceritinib
Other name:CS-1406; LDK378; 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-ylphenyl)-N4-[2-(isopropylsulfonyl)phenyl]-pyrimidine-2,4-diamine;
Molecular formula: C28H36ClN5O3S
Color: White solid
Ceritinib (Zykadia) is a drug for the treatment of lung cancer. It is an ALK inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.
Initial results from a Phase I study investigating the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of LDK378 in 88 patients with ALK+ advanced malignancies, as detected by an FDA-approved test and who had progressed during treatment with, or were intolerant to, crizotinib, were presented at the European Society of Medical Oncology 2012 annual congress. The data showed marked responses in a majority of patients with ALK+ NSCLC. A response rate (including complete response [CR], partial response [PR] and unconfirmed PR) of 80% was observed in the patients who had experienced disease progression after crizotinib treatment.
Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 showed a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib. LDK378 blocks the ALK protein and stops it sending growth signals to cancer cells, which may stop them growing. Ceritinib was approved in April 2014.
Our main products:
Picture of Ceritinib Powder Cas 1032900-25-6:
Package & Shipping:
1. Preferentially DHL or FedEx for quantity less than 50KG; Air shipping for 100KG above; Sea shipping for quantity over 500KG.
2. We can offer the complete package from concept to delivery; arranging everything up until products arrive at your own door or distribution hub.
Delivery can be offered.
- Utilizing your own freight-forwarder
- FOB to a port in China
- CIF to a port near you
1. Supply high quality products with reasonable prices for pharmaceutical factory.
2. In time delivery, Packing pictures and loading video before loading.
3. Various documents(COA, MSDS, ROS, MOA etc.) and factory audit available.
4. Pre-sale consultation and post-sale service available.
5. Provide market informations to make customers fully informed.
Shijiazhuang Dingmin Pharmaceutical Sciences Co., Limited is a professional company ocusing on the R&D, production, marketing and technical service of APIs and Pharmaceutical Intermediates. We have a R&D center and two plants in Shijiazhuang, Hebei Province. Our Products include Active Pharmaceutical Ingredients (API), pharmaceutical and Agrochemical Intermediates and chiral compounds. We have won the trust of a wide range of customers/partners in the industry. Our major products are antineoplastic, cardiovascular and antibiotics and their intermediates.
In order to maintain continuous innovation and R & D capability, we maintain long-term and close cooperation with many research institutions and universities, Our co-production plants are located in Anhui, Jiangsu, Zhejiang and Inner Mongolia. The products have been sold to Europe, America, Southeast Asia and other countries and regions
Having upholding the " integrity, profession , innovation, win-win" as business philosophy, we believe that we are able to be stronger and stronger because of the excellent quality, favorable price and full-hearted service. We would like to sincerely welcome friends from all sectors to co-create a brilliant tomorrow together.
Copyright © 2019 Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd All rights reserved.